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Development of vaccines against Toxoplasma gondii infection in humans is of high priority, given the high bur-
den of disease in some areas of the world like South America, and the lack of effective drugs with few adverse effects. 
Rodent models have been used in research on vaccines against T. gondii over the past decades. However, regard-
less of the vaccine construct, the vaccines have not been able to induce protective immunity when the organism is 
challenged with T. gondii, either directly or via a vector. Only a few live, attenuated T. gondii strains used for im-
munization have been able to confer protective immunity, which is measured by a lack of tissue cysts after challenge. 
Furthermore, challenge with low virulence strains, especially strains with genotype II, will probably be insufficient 
to provide protection against the more virulent T. gondii strains, such as those with genotypes I or II, or those geno-
types from South America not belonging to genotype I, II or III. Future studies should use animal models besides 
rodents, and challenges should be performed with at least one genotype II T. gondii and one of the more virulent 
genotypes.  Endpoints like maternal-foetal transmission and prevention of eye disease are important in addition to 
the traditional endpoint of survival or reduction in numbers of brain cysts after challenge.
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Toxoplasma gondii is a protozoan apicomplexan par-
asite with a worldwide distribution. If contracted during 
pregnancy, T. gondii infection can induce abortion or 
considerable morbidity of foetuses, I the form of mental 
and physical disabilities, and retinal inflammation. The 
disease is normally self-limiting in immunocompetent 
individuals, but inflammation of the retinae can occur. 
Disseminated disease, which is generally fatal if not 
treated, is observed in immunocompromised patients. T. 
gondii is capable of infecting most mammals and birds. 
Transmission to humans is either through consumption 
of food contaminated with tissue cysts and meat products 
from infected animals or by ingestion of oocysts released 
in the faeces of infected cats (Kijlstra & Jongert 2008). 
The benefits of prophylactic immunizations could there-
fore be threefold: (i) prevention of infection or at least of 
clinical disease in humans; (ii) prevention of infection in 
animals raised for human consumption, thereby prevent-
ing transmission; (iii) immunization of domestic cats to 
disrupt the zoonotic cycle and prevent contamination of 
the environment by oocysts. In principle, an effective 
recombinant vaccine against both sexual and asexual 
stages of the parasite should be able to address all three 
targets, but this is hampered by stage specific expression 
of T. gondii proteins. 
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Requirements for human and veterinary vaccines are 
different. For instance, the use of live, attenuated vac-
cines in primates and humans is difficult to envisage 
due to side effects and risks for breakthrough infection 
(Escadillo & Frenkel 1991). Vaccination strategies for 
veterinary vaccines against T. gondii have recently been 
reviewed (Innes & Vermeulen 2006).
Adult acquired infection in immunocompetent hu-
mans probably results in lifelong infection and lifelong 
protection. However, congenital infections tend to re-
lapse and can result in progressive damage, most com-
monly to the retina. Congenital infection is believed to 
only occur in immunocompetent mothers, if infected for 
the first time during pregnancy. However, there is now 
accumulating evidence that a small number of women 
transmit the parasite to their foetus when chronically in-
fected (Awan 1978, Vogel et al. 1996, Silveira et al. 2003, 
Kodjikian et al. 2004). 
In mice, chronic infection with the cyst-forming 
Beverley strain provided clinical immunity to superin-
fection with the lethal T. gondii strain RH. Fully virulent 
RH parasites could be recovered from mouse brain more 
than one year after challenge (Reikvam & Lorentzen-
Styr 1976). We lack the tools to determine whether super-
infection in humans may override the immunity induced 
by primary infection. It cannot be excluded that better 
tools may show that clinical immunity after the primary 
infection is not complete and that a subsequent challenge 
with a sufficiently high dose or different genotype may 
induce superinfection. Hypothetically, a mother may be 
susceptible to superinfection, while providing sterile im-
munity to her unborn child. It therefore seems that natu-
ral infection with T. gondii results in life long protection 
against clinical disease from new infection and strong 
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protection against congenital infection. However, natu-
ral infection might not result in sterile immunity of the 
healthy individual when recurrent eye disease is a prob-
lem. Therefore, despite clinical immunity against new 
infection, the individual would not be protected from 
“flare ups” due to tissue cysts, which can remain for 
decades after the primary infection. The apparent strong 
clinical immunity after a single infection suggests that a 
vaccine should be able to confer protection against clini-
cal symptoms and maternal-foetal transmission.
There is no standard protocol for the evaluation of vac-
cines against T. gondii and in animal models the T. gondii 
isolate and dose used for challenge varies between studies, 
making comparison difficult. This review looks at studies 
in animal models with survival and cyst number as pri-
mary endpoints, and discusses the use of animal models 
with the aim of developing vaccines for humans.
Inactivated parasites, crude or purified antigens and 
recombinant antigens
An early study of guinea pigs immunized with inacti-
vated whole T. gondii tachyzoites found some protection 
against challenge; animals infected with live T. gondii 
were protected against subsequent challenge (Cutchims 
& Warren 1956). A study using formalin fixed whole T. 
gondii tachyzoites found a significantly increased surviv-
al of vaccinated mice after challenge (Krahenbuhl et al. 
1972). Later studies showed that immunization with live, 
non-attenuated T. gondii resulted in complete protection 
against heterologous infection (Pettersen 1988). Ten tri-
als in animal models using inactivated T. gondii, crude or 
purified antigen extracts performed between 1972-2005 
have recently been reviewed (Schaap et al. 2007).
The immunodominant stage-specific surface antigen 
1 (SAG1) expressed on the surface of tachyzoites has 
been extensively investigated. SAG1 affinity purified 
from the T. gondii RH strain, combined with adjuvants, 
provided high survival rates and significant reductions 
in brain cyst loads in mice (Bülow & Boothroyd 1991, 
Khan et al. 1991, Debard et al. 1996, Velge-Roussel & 
Boothroyd 1997, 2000). It is worth noting that the high-
est protection achieved with this native antigen was ob-
tained with intranasally delivered SAG1; 90% survival 
and no brain cysts in survivors when administered with 
the adjuvant QuilA (Khan et al. 1991) and 85% reduction 
in brain cyst load when adjuvanted with Cholera Toxin 
(Debard et al. 1996). Protection efficacy was due to the 
CD8+ T cell fraction (Khan et al. 1991). 
Recently, MIC1 and MIC4 proteins purified from 
parasite extracts were shown to reduce the number of 
brain cysts and to produce an 80% survival rate and a 
68% reduction in brain cyst load in C57BL/6 mice, after 
challenge with the T. gondii ME49 isolate (Lourenço et 
al. 2006). Interestingly, the most promising protection 
with purified parasite components was not obtained in 
mice but in cats, where an intranasally administered 
rhoptry extract, formulated in QuilA, could provide ster-
ile immunity to oocyst shedding (Garcia et al. 2005).
With the advent of recombinant protein technology, 
T. gondii antigens produced by bacteria were evaluat-
ed in vaccines. Vaccines based on recombinant SAG1 
could protect against acute toxoplasmosis (Petersen et 
al. 1998, Yang et al. 2004, Siachoque et al. 2006) and 
brain cyst formation (Letscher-Bru et al. 1998, Bonen-
fant et al. 2001). A study addressing protection against 
congenital toxoplasmosis found that recombinant SAG1 
protein protected BALB/c mice against maternal-foetal 
transmission of T. gondii, but increased the number of 
infected foetuses by 50% in CBA/J mice, underlining 
the importance of different outcomes in different in-
bred mice models (Letscher-Bru et al. 2003). Recom-
binant GRA4 and ROP2 adjuvanted with Alum provided 
protection against brain cysts in C57BL/6 mice, while 
only the latter antigen provided protection in C3H mice 
(Martin et al. 2004). Differences in outcome depending 
on genetic background were also reported for a ROP2-
HSP83 (Leishmania infantum) fusion protein where 
more than 80% reduction in brain cysts was observed in 
C3H/HeN mice, but not in C57BL/6 mice (Echeverria et 
al. 2006). On the other hand, a study using recombinant 
GRA2 and GRA6, adjuvanted with monophosphoryl A 
(MPL) found a significant reduction in the number of 
brain cysts in GRA2, but not GRA6, immunized CBA/J 
mice challenged with the T. gondii Prugniaud isolate. 
Combination of both antigens did not lead to enhanced 
protection (Golkar et al. 2007). 
Recently, two studies using adjuvanted mixtures of 
recombinant proteins achieved a high level of protec-
tion against chronic toxoplasmosis. A mixture of SAG1, 
GRA1 and MAG1, adjuvanted with Freund’s Complete 
Adjuvant, reduced brain cyst burden by 89% (Gatkows-
ka et al. 2008) in BALB/c mice. Additionally, a mixture 
of GERBU adjuvanted GRA7 and a MIC2-MIC3-SAG1 
chimeric protein provided a 79% reduction in brain cysts 
in outbred SWISS mice following challenge with T. gon-
dii 76K (Jongert et al. 2008).
These studies primarily used survival and protection 
against brain cyst formation as the endpoint and found 
a significant degree of protection. Complete protection 
against acute disease and/or chronic toxoplasmosis in 
mice has only been obtained using strong adjuvants such 
as Freund’s Complete Adjuvant and QuilA (Khan et al. 
1991, Brinkmann et al. 1993, Mishima et al. 2001a). Ta-
ble I shows studies using inactivated parasites or puri-
fied and recombinant antigens for antigen delivery. 
Live, attenuated T. gondii vaccines
Immunization with live, attenuated T. gondii para-
sites conferred better protection compared to inactivat-
ed tachyzoites independent of the adjuvant used, with 
the exception of challenge with one mutant strain TS-1 
(Waldeland & Frenkel 1983). 
In 1941, a Toxoplasma strain was isolated from the 
brain of a patient with a fatal case of congenital toxoplas-
mosis (Sabin 1941). This strain, named RH, is defective 
in tissue cyst formation and was found to be extremely 
virulent in mice and other laboratory animals. The RH 
strain is the archetype of all Toxoplasma strains and has 
a Type I genome. Almost 30 years later, chemical muta-
genesis of the RH strain resulted in the temperature sen-
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sitive, T. gondii isolate TS-4 (Pfefferkorn & Pfefferkorn 
1976). Vaccination with this strain provided a significant 
protection against tissue cyst formation and partial pro-
tection against congenital toxoplasmosis (McLeod et al. 
1988), as well as increased survival during acute toxo-
plasmosis (Gazzinelli et al. 1991). This strain provides 
the basis for the immunological insight that protection 
against toxoplasmosis is mediated by CD4+ and CD8+ 
IFN-γ producing T-cells (Gazinelli et al. 1991). The RH 
strain was shown to be safe for use in a pig model and was 
undetectable in the tissues as soon as three weeks post 
vaccination (Lindsay et al. 1993). Although promising as 
a vaccine strain and shown to be safe for use in immuno-
competent primates, the strain failed safety tests in preg-
nant Aotus monkeys (Escajadillo & Frenkel 1991). 
In 1988 a tissue cyst defective strain, S48, was iso-
lated from an infected and aborted ovine foetus. S48 
became an incomplete, attenuated strain following ex-
tensive (x 3000) passages in the laboratory (Wilkins et 
al. 1988). Vaccination of sheep with S-48 afforded a 75% 
reduction of abortion, a reduced neonatal mortality and 
higher birth weight (Buxton et al. 1991). The S-48 strain 
has since been developed into a commercial vaccine used 
in sheep to prevent abortions. Whether vaccination with 
S-48 also prevents tissue cyst formation upon challenge 
with cyst forming strains remains undetermined. 
In recent work, intramuscular vaccination with CpG-
adjuvanted RH tachyzoites could protect 52% of chal-
lenged pigs and provide sterile immunity against tissue 
cyst formation (Kringel et al. 2004). In 2002, a T. gon-
dii uracil auxotroph mutant was found to be completely 
avirulent in mice, including in IFN-gamma KO mice; this 
mutant strain could induce complete protection against le-
thal injection with T. gondii RH (Fox & Bzik 2002). 
Recently, a T. gondii strain attenuated by the dele-
tion of the mic1 and mic3 genes was used to immunize 
OF1 mice. After challenge with the 76K T. gondii iso-
late, greater than 96% reduction in the number of brain 
cysts, as well as reduced transmission to foetuses, was 
observed. In spite of these promising results, no sterile 
immunity was obtained (Ismael et al. 2006). A review 
of T. gondii knock out strains used for immunization 
shows that although most offer protection against lethal 
challenge and can reduce cysts burden, some result in 
increased mortality (Schaap et al. 2007).
Sterile immunity to tissue cysts induced by live, de-
fective T. gondii strains has not been obtained in mice 
(Schaap et al. 2007), but has been achieved in pigs (Krin-
gel et al. 2004). In addition, sterile immunity against 
oocyst shedding was obtained in 84% of cats vaccinated 
with an oocyst deficient strain, T263. However, this vac-
cine has never been commercialised (Frenkel et al. 1991).
Plasmid vaccines
DNA vaccines have the particular capacity to induce 
CD4+ T-lymphocyte and CD8+ cytotoxic T-lymphocyte 
(CTL) responses against the antigen of interest. As 
protection against T. gondii has been associated with 
a Th1 response, this vaccination strategy has received 
considerable attention. The choice of the vaccine vec-
tor should be further investigated, since a large number 
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of plasmids and live vectors have been used for antigen 
delivery. However, a comparative analysis between dif-
ferent vectors has never been performed,and thus it is 
very difficult to determine which is most appropriate. 
A discussion of the different vectors used is beyond the 
scope of this review.
Antigen delivery using plasmids coding for T. gon-
dii SAG1 protein, or a fragment thereof, initially showed 
100% protection against lethal challenge (Nielsen et al. 
1999, Angus et al. 2000, Couper et al. 2003). This was 
correlated with a CTL response against this antigen. 
SAG1 has been a prime antigen because of its immu-
nodominance.  Furthermore, although plasmid vaccines 
based on SAG1 can provide protection against lethal in-
fection and reduce cyst numbers, they have not been able 
to induce a sterile immunity against infections with cyst 
forming T. gondii isolates (Angus et al. 2000). Other pro-
teins evaluated in DNA vaccines mostly originate from 
dense granules, rhoptries or micronemes. DNA vaccina-
tion with GRA1, GRA7 or ROP2 provided partial pro-
tection against acute and chronic infection with T. gondii 
76K and IPB-G in C3H/HeN mice (Vercammen et al. 
2000). GRA1 partially protected against acute toxoplas-
mosis by generation of a cytolytic CD8 response against 
this antigen (Scorza et al. 2003). DNA vaccination with 
GRA4 was shown to be as efficient in protection against 
brain cyst formation as the GRA4 protein adjuvanted 
with Alum (Martin et al. 2004).  
Of critical importance was the discovery that the 
combination of multiple DNA vaccines in a single for-
mulation could significantly enhance cellular immune 
responses and protection, as compared to the single 
gene vaccines. Prolonged protection against acute toxo-
plasmosis upon infection with T. gondii RH in BALB/c 
mice was reported for a cocktail DNA vaccine combin-
ing SAG1 with ROP2 (Fachado et al. 2003a), but not for 
the single gene DNA vaccines. Similarly, enhanced pro-
tection was observed in mice after immunization with 
a plasmid based combination of GRA4 and SAG1. This 
vaccine reduced mortality and brain cyst numbers in 
C57BL/6 mice, but failed to induce sterile immunity or 
complete protection after challenge with the type II 76K 
T. gondii isolate (Mévélec et al. 2005). A study combin-
ing the two bradyzoite antigens BAG1 and MAG1 in a 
cocktail DNA vaccine also found a significant reduction 
in the number of brain cysts (62%), but no sterile immu-
nity (Nielsen et al. 2006). A similar study, using a com-
bination of antigens delivered as plasmids coding for 
regions of microneme proteins including MIC2, MIC3, 
MIC4, M2AP and AMA1, resulted in a significant re-
duction (84%) of the number of cysts, but not sterile im-
munity (Beghetto et al. 2005). Recently, a GRA7 DNA 
vaccine was found to be correlated with high-level pro-
tection against brain cyst formation and a cocktail DNA 
vaccine with a combination of GRA1 and GRA7 could 
reduce the T. gondii 76K brain cyst burden by 89% in 
C3H/HeN mice, but no sterile immunity was obtained 
(Jongert et al. 2007). Interestingly, the same GRA1-
GRA7 cocktail DNA vaccine was able to provide sterile 
protection against tissue cyst formation in two of three 
vaccinated pigs (Jongert et al. 2008a).
Other studies have combined T. gondii antigens on 
a single DNA vaccine plasmid. Chimeric SAG1-ROP2 
and multi-antigenic DNA vaccines containing SAG1, 
ROP2 and GRA2 showed significant protection levels 
against acute toxoplasmosis in BALB/c mice. Addition 
of IL-12 (but not cholera toxin) as a genetic adjuvant 
could enhance the protective Th1 response and pro-
tection (Zhang et al. 2007a, Cui et al. 2008, Xue et al. 
2008a, b). Table II shows studies using plasmid vectors 
for antigen delivery.
Live, attenuated vectors 
Since T. gondii is an intracellular parasite, strategies 
that mimic the intracellular niche of T. gondii have been 
evaluated using live or attenuated vectors. The first re-
port on the use of a vector for the delivery of a T. gon-
dii antigen used a recombinant Mycobacterium bovis 
BCG expressing GRA1. This strategy was able to elicit a 
GRA1-specific cellular immune response in subcutane-
ously primed sheep, but not in outbred mice (Supply et 
al. 1999). No significant protection was reported after 
oocyst challenge. The same strategy using ROP2 in a 
BCG vector was partially successful, since vaccinated 
animals had significantly increased survival after chal-
lenge with the T. gondii RH isolate, as compared with 
the controls (Wang et al. 2007).
Attenuated Salmonella strains have been evaluated 
for the delivery of plasmid DNA by oral immunisation. 
Delivery of a SAG1-SAG2 fusion protein linked to chol-
era toxin A2/B via an attenuated Salmonella typhimu-
rium strain afforded 40% survival in BALB/c mice after 
challenge with the T. gondii RH isolate, compared with 
100% mortality in the SAG1-2 immunized group (Cong 
et al. 2005). Recently, 10% and 20% survival was ob-
tained with an attenuated S. typhimurium strain deliver-
ing a SAG1 DNA vaccine in ICR mice, while all naïve 
mice succumbed to infection (Qu et al. 2008).
In addition to intracellular bacteria, recombinant vi-
ruses have also been evaluated as vectors for vaccination 
against toxoplasmosis. Immunisation with recombinant 
adenovirus expressing SAG1, SAG2 or SAG3 has been 
tested in BALB/c mice and could elicit the Th1 cellular 
immune responses against all three antigens. Vaccina-
tion of mice with a mixture of these three adenoviruses 
could reduce the brain cyst burden by 80% upon chal-
lenge with T. gondii P-Br, but could not protect against 
acute toxoplasmosis after challenge with T. gondii RH 
(Caetano et al. 2006). Prime-boost experiments using a 
GRA4 construct delivered by a recombinant plasmid and 
attenuated vaccinia virus construct (Zhang et al. 2007b) 
showed 100% survival in the heterologous prime boost 
group after challenge, followed by a 70% survival in the 
plasmid-plasmid immunized group. The heterologous 
prime boost group also showed the largest reduction in 
brain tachyzoite counts after challenge. However, the 
vaccine failed to induce sterile immunity against tis-
sue cysts. A modified vaccinia ankara vector express-
ing ROP2 could increase the life span after lethal chal-
lenge with T. gondii RH (Roque-Resendiz et al. 2004). 
Recently, 60% survival was obtained after vaccination 
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with a SAG1 expressing Pseudorabies virus, in mice 
challenged with T. gondii RH (Liu et al. 2008). Table III 
shows studies using live, attenuated vectors.
Adjuvants
The word adjuvant is derived from the latin word ad-
jutants, which means ancillary. Adjuvants have generally 
been defined as substances that enhance the immunoge-
nicity of the antigenic vaccine components. Adjuvants 
have been categorised into three groups, (i) active immu-
nostimulants, (ii) carrier proteins that provide T cell help 
or (iii) vehicle adjuvants such as emulsions and vesicles 
that serve as a matrix for antigens, as well as stimulate the 
immune response (Petrovsky & Aguilar 2004). However, 
as components of experimental vaccines have become 
increasingly refined, often to the point of single proteins 
or small peptides, a fundamental immunological role has 
emerged for vaccine adjuvants consistent with catego-
ry (i). The identification of this role was only possible 
through our increased understanding of T cell activation 
and the development of a 3-signal model of activation 
(Curtsinger et al. 1999). CD4 T cells, through their T cell 
receptor (TCR), encounter processed antigenic peptides 
bound to MHC class II on the surface of antigen present-
ing cells, “signal 1’’. For successful activation, this must 
be accompanied by co-stimulation through the ligation 
of additional molecules on the surface of the T cell and 
APC, “signal 2”. A third signal has been proposed that 
determines the nature of the T cell activation, “signal 
3”. Thus a “signal 3”, consisting of IL-12, will directs 
the development of Th1 cells, whereas IL-4 will direct 
Th2 development (Constant & Bottomly 1997). More re-
cently, TGF-β has been recognised as a signal for Treg 
cell differentiation and a combination of TGF-β/IL-6 /
IL-23 has been recognised for directing the differentia-
tion of Th17 cells (Bommireddy & Doetschman 2007, 
Stockinger & Veldhoe 2007). During natural infections, 
these signals are normally elicited through components 
of pathogens. These components logically have been re-
tained in attenuated vaccines and many crude vaccine 
formulations. The hope is that where these are absent, 
in defined protein or peptide vaccine formulations, they 
can be replaced or mimicked by an appropriate vaccine 
adjuvant that elicits the appropriate “signals 2 and 3”. 
Many of the pathogen components that elicit “signals 
2 and 3” are TLR ligands, while some interact through 
other receptors such as retinoic acid inducible gene-like 
receptors or NOD-like receptors (Ishii & Akira 2007). 
CD8 T cells, unlike CD4 T cells, have been reported 
to be activated without “signal 2t”, although “signal 2” 
lowers the threshold for activation through TCR ligation 
alone. However, further studies indicate that “signal 3”, 
normally IL-12 or type-1 interferon, is necessary for the 
development of the CD8 T cells’ir cytolytic ability. Im-
portantly, and potentially relevant to T. gondii infection, 
“signal 3” is not required for their CD8 T cell expansion 
or IFN-γ production (Curtsinger et al. 2005, Williams & 
Bevan 2007). In the context of initiation of protective im-
munity to T. gondii, naïve CD8 cells have been demon-
strated to require IL-2 from CD4 cells for their develop-
ment (Gazzinelli et al. 1991). Another issue that has been 
described in the literature as important for initiating CD8 
T cells, is delivery of the antigen into the endogenous 
antigen-processing pathway, where it can become effi-
ciently presented in the context of MHC class 1. However, 
the discovery of cross-presentation, where an exogenous 
antigen can cross from the exogenous pathway into the 
endogenous pathway in dendritic cells would arguably ne-
gate this previous concern (Vyas et al. 2008). 
A very efficient vaccine was developed using the 
ubiquitin-proteasome system to immunize mice with a 
chimeric DNA encoding a fusion protein between mu-
rine ubiquitin and the T gondii antigen SAG1. This study 
found that the vaccine induced strong protection, as 
measured by survival after challenge with the RH strain 
(Ishii et al. 2006). The advantage of the ubiquitin system 
is that it acts as a chaperone, ensuring that more of the 
T. gondii antigen is degraded and presented and thus en-
hances antigen presentation.
As most vaccine studies were carried out before 
many of the above facts were known, the selection of 
adjuvant has not, and could never have been completely 
rational. Furthermore the relatively slow progresses in 
adjuvant research, including the only recent realisation 
that adjuvants play a role in initiating “signals 2” and 
a precluded their rational selection. For example, it has 
only recently been demonstrated that ALUM, the first 
adjuvant licensed for use in humans, stimulates the 
NOD-like receptor, pyrin domain containing 3 (Nlrp3)-
inflammasome (De Gregorio et al. 2008). Thus most 
adjuvants were chosen from empirical evidence of their 
ability in other systems. 
The efficacy of each adjuvant employed is difficult 
to assess due to the many other confounding factors that 
varied in each reported study. For the reasons discussed, 
the use of adjuvants has traditionally been linked to pro-
tein vaccines, be it recombinant proteins or a protein 
fraction purified from the parasites, rather than killed or 
attenuated parasites. However, adjuvants for DNA plas-
mid vaccines are now being studied.
A recent review categorises adjuvants into: mineral 
salt adjuvants (e.g., ALUM); tensoactive adjuvants (e.g., 
QuilA), bacteria derived adjuvants (e.g., LPS), adjuvant 
emulsions (e.g., FCA) liposome adjuvants (probably bet-
ter referred to as vesicular adjuvants so as to include 
NISV); polymeric microsphere adjuvants; carbohydrate 
adjuvants and cytokine adjuvants (Petrovsky & Aguil-
lar 2004). Each of these has been used in experimental 
vaccines for toxoplasmosis over the years with varying 
degrees of success (Khan et al. 1991, Debard et al. 1996, 
Petersen et al. 1998, Desholme et al. 2000, Martin et al. 
2004, Cong et al. 2005, Garcia et al. 2005, 2007, Mévé-
lec et al. 2005, Golkar et al. 2007, Zhang et al. 2007a, b, 
Cui et al. 2008, Jongert et al. 2008b, Xue et al. 2008a, 
b). A common theme emerges that adjuvants do increase 
the immune response to the antigen administered and 
usually, but not always, induce a degree of protection to 
a subsequent challenge. However, the inability of any 
antigen-adjuvant combination to afford complete ster-
ile protection most likely indicates that antigen/epitope 
identification is insufficiently advanced.
Since many vaccine studies have explored the use of 
plasmid DNA for vaccination, other adjuvants systems 
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have been considered. Again many of these rely on TLR 
ligands, including CpG which is a ligand of TLR9 (Zim-
mermann et al. 2008), or genes for cytokines (e.g., IL-12 
or GM-CSF) that when expressed, function directly as 
the third signal, or induce the third signal. 
Recently, a number of components from T. gondii 
have been found to activate TLRs. For example, T. gondii 
has a variety of GPI-anchored proteins, which in theory 
can interact with TLR2 and 4 (Debierre-Grockiego et 
al. 2007). T. gondii HSP70 can also interact with TLR4 
to induce maturation of dendrites (Aosai et al. 2006). 
Profilin from T. gondii can ligate TLR11 and induce IL-
12 production (Yarovinsky et al. 2005). TLR11 is only 
present in certain mammalian species such as mice, 
but absent from others including humans. However T. 
gondii cyclophilin 18 has been demonstrated to bind the 
CCR5 receptor and induce IL-12 production (Aliberti et 
al. 2003). These molecules could be considered as “en-
dogenous” adjuvants and may have promise as vaccine 
adjuvants, especially for T. gondii vaccines. An early 
study using purified SAG1 as a vaccine in mice found 
that it could function in the apparent absence of adju-
vant, a fact that can now be retrospectively explained 
by this molecule containing a GPI-anchor, making it an 
“endogenous” adjuvant (Khan et al. 1991).
The use of IL-12 as an adjuvant and the use of chime-
ric administration systems like the ubiquitin-SAG1 con-
struct to enhance antigen processing and presentation 
needs further attention, combined with T. gondii profilin 
and cyclophilin 18 as TLR binding antigens.
Other than providing or eliciting the second and third 
signals, vaccine adjuvants that are capable of mucosal 
delivery may be of particular interest in T. gondii vac-
cines as infection most often occurs through this route. 
In this respect bilosomes, a mixture of non-ionic sur-
factant and bile salts in a vesicular formulation may 
hold promise (Conacher et al. 2001). Such systems may 
require additional components to generate appropriate 
second and third signals. 
DISCUSSION
Protein vaccines are known to induce primarily B-
cell responses and thus are highly efficient for compet-
ing infections that can be antagonized by neutralizing 
antibodies. DNA vaccines are now known to induce pri-
marily strong cytotoxic T cell responses and have been 
demonstrated to have limited capacity in overall protec-
tion, especially when used in primates. Immunological 
restriction very likely limits the development of a vac-
cine, either protein or DNA, against T. gondii since this is 
a parasite with various life cycles and antigenic variation. 
The immunological response against T. gondii clearly is 
a strong cytotoxic T cell response (Gazzinelli et al. 1991, 
1992, Hakim et al. 1991, Denkers et al. 1993). However, 
whether the humoral response against the parasite is of 
diagnostic value or may add to protection remains under 
debate (Sayles et al. 2000, Johnson et al. 2004).
The importance of stimulating both the humoral and 
the cellular immunity when applying a T. gondii vaccine 
might be best reflected by 90% survival achieved in a 
study where a DNA prime regimen was followed by a 
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protein boost (Zhang et al. 2007a, b). However, sterile 
immunity was not achieved by this heterologous prime-
boost regimen, or by any of the other up-to-date experi-
mental settings.
The apparent complete protection against new in-
fections in immunocompetent individuals after natural 
infection, and the cross protection in animals after natu-
ral infection, show that protective immunity can be de-
veloped. Furthermore, this evidence also suggests that 
a vaccination derived from a single clonal lineage of T. 
gondii could protect against challenge with any of the 
other lineages. However this is still open to debate, as 
we are lacking tools to evaluate the immune response 
and parasite dissemination after reinfection. The studies 
discussed here illustrate that most antigens can induce 
some degree of protection measured both by increased 
survival after lethal infection with a virulent parasite 
and by a reduction in the number of brain cysts after 
challenge with a cyst forming T. gondii isolate. How-
ever, meaningful comparison of the overall protective 
efficacy between the different studies in mice is clearly 
hampered by the heterogeneity of experimental proto-
cols being used over the last years. Sterile immunity and 
complete protection against acute transplacental infec-
tion and protection against congenital disease has not 
been obtained in mice, despite intensive efforts. 
It important to note that sterile immunity against tis-
sue cyst formation in mice was obtained by Mishima et 
al. (2001b) and Couper et al. (2003), but these mice were 
not absolutely protected against lethal challenge or con-
genital infection, respectively. These data beg the ques-
tion of whether the same immunological mechanism is 
correlated with protection against acute, chronic and 
congenital protection.
In sharp contrast, sterile immunity against tissue 
cyst formation and oocyst shedding has been obtained in 
pigs (Kringel et al. 2004, Garcia et al. 2005, Jongert et al. 
2008a) and cats, respectively (Frenkel et al. 1991, Garcia 
et al. 2007). The highest protection against congenital 
disease, however, was obtained in a rat model (Zenner 
et al. 1999). However, in these models, the correlates of 
protection have not been elucidated. Most studies have 
been performed in inbred mice, simply due to the sim-
plicity and cost of the model. However, better protection 
in outbred pigs, which are closer to humans, raises the 
question of whether the mouse model is the most appro-
priate for studies aimed at developing a human vaccine.
Standardisation of several experimental parameters 
would be helpful in order to derive conclusions from stud-
ies using varying antigens and/or varying adjuvants. Chal-
lenge protocols should use the route of administration that 
is the most commonly found in mammals: the oral route, 
either by feeding tissue cysts or oocysts. It must be con-
sidered whether the usage of brain derived tissue cysts 
equivalently reflects the ingestion of cysts from meat.
Moreover, a number of different T. gondii strains are 
used for challenge experiments in vivo. It is now estab-
lished that T. gondii strains differ in their virulence in 
mammals (Sibley & Boothroyd 1992, Boyle et al. 2006). 
Hence, it is important for comparison and standardiza-
tion of infection challenge protocols, and to agree on the 
use of a number of strains displaying different virulence 
and to test these strains in parallel experiments under 
standardized read-out conditions. In particular, now that 
Brazilian Toxoplasma strains are emerging as a distinct 
and more virulent type than the European type I/II/
III strains, and many other Toxoplasma genotypes are 
emerging in human congenital cases and animal reser-
voirs worldwide, it is important to use strains originating 
from different parts of the world in protection assays to 
ensure cross-type and cross-virulence protection against 
toxoplasmosis.
The genetic background of experimental animals 
influences the outcome of vaccination protocols and 
challenge infections. The use of inbred mouse strains 
for challenge experiments does not reflect the genetic 
situation in animals or humans. If inbred mouse strains 
are used, the same vaccine should be tested in a number 
of possible H2 settings, for example BALB/c for H2k-
d, C57Bl/6 for H2k-b and C3H for H2k-k. The use of 
outbred strains might better overcome immunological 
restrictions of the major histocompatibility complex. 
Moreover, when thinking of the development of a T. gon-
dii vaccine for human use, genetically engineered mice 
expressing human rather than mouse H2 (Taneja & Da-
vid 1998) might be helpful in order to draw conclusions 
of vaccine efficacy in humans. Despite the high number 
of vaccine studies in mice, only a few have addressed 
protection against congenital infection. 
There is an urgent need to compare the efficacy of 
different adjuvants for use in vaccines against T. gondii 
using standardized protocols i.e., antigen formulation 
and animal models. The importance of this is illustrated 
by a study of different adjuvants used for immunization 
against hepatitis B using a recombinant hepatitis B SAG 
(Vandepapelierea et al. 2007). The authors found that 
CpG was inferior to MPL, suggesting that adjuvants that 
help signal antigen processing through TLR4 are more 
efficient compared to adjuvants that direct antigen pro-
cessing through TLR9.
For the development of a vaccine that can prevent 
toxoplasmosis, there have been a number of recent tech-
nological and knowledge-based advances that may prove 
important.  First, the completion of the T. gondii genome 
project should provide the complete “antigenome” of T. 
gondii. This will also allow comparison of the “antige-
nome” between major T. gondii lineages. Second, the 
mode of action for traditional adjuvants and how this 
relates to T cell activation will contribute to the develop-
ment of new and improved adjuvants based on TLR and 
other (innate receptor) ligands. Third, the development of 
improved read outs of vaccine efficacy, such as parasite 
multiplication, using advanced imaging techniques (e.g., 
Xenogen camera and luciferase expressing parasites) 
will improve our ability to identify effective vaccines. 
Finally, the ability to analyse the immune response in 
relatively high through put systems such as quantitative 
Real Time PCR arrays and cytokine bead arrays will 
further guide vaccine development strategies.
Currently, studies have not been able to induce ster-
ile immunity in mice. Varying degrees of protective im-
munity against lethal challenge and reduction in brain 
cyst loads have been achieved with most antigens.
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Thus it seems that the answer may not lie in the choice 
of antigen and studies of different adjuvants therefore 
must have high priority. 
Protocols of vaccine studies need be standardized in 
the future and we propose the following guidelines as 
a minimum: (i) vaccine constructs aiming at protection 
against cyst forming T. gondii in animal models should 
have brain cyst load as a main end point, not survival; 
(ii) infection with cysts simulating oral infection can be 
done using brain emulsion, but this needs to be admin-
istered by the oral route; (iii) challenges should be per-
formed in parallel, using at least two T. gondii isolates 
belonging to two different lineages. Protection against 
the least pathogenic genotype II is not enough to dem-
onstrate protective immunity against other genotypes; 
(iv) immunization should be performed in a number of 
inbred mouse strains, preferably BALB/c and C57BL/6 
or C3H/HeN; (v) the vaccine efficacy should also be 
tested in outbred mice, since this more closely reflect 
the genetic situation of animals and humans.
In general, next generation studies should address 
standardizing the immunization protocol and compar-
ing the immunogenicity of a fixed antigen delivered with 
different vectors and adjuvants in order to solve the com-
plex puzzle of the T. gondii vaccine. 
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